ArticleInternational ophthalmology2025
An assessment of the prevalence of cannabis use in eye clinic patients and its implications on glaucoma diagnosis and management.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntraocular pressure (IOP) is a major clinical marker used to diagnose glaucoma and monitor its treatment. Marijuana use can confound IOP measurements by temporarily lowering the IOP, potentially leading to missed diagnoses of glaucoma or a false sense of effective treatment. Therefore, factors that may affect diagnosis or treatment of glaucoma need to be characterized and considered. We aim to assess the prevalence of cannabis use among patients presenting for an eye examination.
methodsA survey was administered to 134 patients arriving for their regular ophthalmic appointments, from Oct 2022 to Jan 2023 and Jul 2024-Aug 2024 in four eye clinics at the University of Minnesota (UMN).
resultsAmong study patients, 15.7% reported recent use of marijuana (< 1 month), 8.2% described themselves as regular users, and 4.5% of patients reported using it every day. Just under half (44.2%) of glaucoma patients indicated they were interested in using marijuana for their glaucoma. Patients that used marijuana less than 24 h from their eye exam were significantly more likely to know that marijuana decreases intraocular pressure (IOP) (p = 0.02). Beliefs that marijuana is effective (p = 0.016), lowers IOP (p = 0.011), and has fewer side effects than glaucoma medications (p = 0.014) were predictive of interest in marijuana use. In contrast, beliefs that marijuana has negative physical (p = 0.041) and mental (p = 0.003) health effects were predictive of disinterest in use.
conclusionThese findings indicate need for increased patient screening for recent marijuana use so ophthalmologists may contextually assess IOP and educate patients on marijuana's effects on the diagnosis and treatment of glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.